Neos Therapeutics, a late stage biotech developing formulations of approved therapies for ADHD, filed on Friday with the SEC to raise up to $69 million in an initial public offering.
The Grand Prairie, TX-based company, which was founded in 1994 and booked $1 million in sales for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol NEOS. Neos Therapeutics initially filed confidentially on 4/27/2015. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
Help employers find you! Check out all the jobs and post your resume.
